Mach7 Boosts ARR and Expands Partner Network in Q4 FY26

Strong Cash Flow and Recurring Revenue Growth

Mach7 Technologies (ASX:M7T) closed FY26’s final quarter with a notable shift from restructuring to execution, reporting a positive operating cash flow of A$1.1 million and ending June 2026 with a solid cash balance of A$19.9 million and zero debt. This marks the third consecutive quarter of cash flow positivity, underscoring the company’s improved operational discipline.

The company’s annual recurring revenue (ARR) run rate climbed to A$23.5 million, up 7.6% in constant currency compared to a year earlier. This growth reflects expansions, add-ons, and new customer go-lives, signaling steady progress in Mach7’s transition toward a subscription-based business model that prioritises predictable, high-quality recurring revenue.

Subscription Deals and Product Deployments Accelerate

Mach7 secured two significant five-year subscription agreements in the quarter: a A$2.8 million expansion licence with a leading academic medical centre and a A$1.7 million subscription with AMRADNET, a US teleradiology provider. The latter deal notably slashed deployment time to just 45 days, one of the shortest sales-to-deployment cycles in Mach7’s history, reflecting the company’s operational improvements and commercial execution.

Additionally, the first production deployment of Mach7’s next-generation Flamingo orchestration platform went live with UnityPoint Health, validating the company’s enterprise imaging architecture designed to integrate imaging data across multiple systems and enable AI-driven workflows.

Expanding Partner Ecosystem and Interoperability Milestones

Mach7 broadened its commercial reach through a new partnership with Howard Medical, which provides indirect access to more than 3,700 hospitals and healthcare organisations in the United States. This relationship leverages Howard Medical’s established healthcare IT channels to identify new enterprise imaging opportunities.

On the interoperability front, Mach7’s eUnity enterprise imaging viewer achieved a key milestone by being listed in the Epic Connection Hub. This listing facilitates seamless integration of Mach7’s zero-footprint image viewing technology into Epic’s widely used clinical workflows, enhancing accessibility for physicians and radiologists at the point of care.

Cost Control and Outlook

While revenue for FY26 is expected to be approximately 15% below FY25 due to delayed capital deal conversions, Mach7 has managed to reduce operating expenses by around 10% through improved cost control. The company balanced cost discipline with targeted investments in AI, product innovation, and commercial capabilities to underpin growth in FY27.

CEO Teri Thomas highlighted the company’s progress in delivering software faster, improving product quality, and strengthening customer engagement. Though challenges remain, Mach7 is positioning itself as a more disciplined player with an increasingly differentiated product offering in the competitive enterprise imaging software market.